Clene’s cash, cash equivalents and marketable securities totaled $35.0 million as of December 31, 2023, compared to $23.3 million as of December 31, 2022. Clene expects that its resources as of December 31, 2023, will be sufficient to fund its operations into the fourth quarter of 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLNN:
- Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
- Clene Announces Breakthrough CNM-Au8 Treatment Results
- Clene presents clinical results of CNM-Au8 30mg treatment
- Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
- Clene’s CNM-Au8 Shows Promise in ALS Survival Rates